PSX
24
2
GRMN
53
3
WFC
58
8
DE
49
3
EQT
47
13
JBHT
46
4
TXT
46
4
NI
63
5
EMR
57
7
WBA
41
3
INTC
35
4
APA
30
5
TROW
37
8
WM
53
2
ORCL
49
3
AIG
38
5
BEN
36
4
DD
44
2
HPQ
55
3
AEE
51
3
PSX
24
2
GRMN
53
3
WFC
58
8
DE
49
3
EQT
47
13
JBHT
46
4
TXT
46
4
NI
63
5
EMR
57
7
WBA
41
3
INTC
35
4
APA
30
5
TROW
37
8
WM
53
2
ORCL
49
3
AIG
38
5
BEN
36
4
DD
44
2
HPQ
55
3
AEE
51
3
Financhill
Back

Novo Nordisk AS 10K Form

Sell
23

NVO
Novo Nordisk AS

Last Price:
$85.00
Seasonality Move:
6.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NVO News And Ratings

See the #1 stock for the next 7 days that we like better than NVO

NVO Financial Statistics

Sales & Book Value

Annual Sales: $33.7B
Cash Flow: $4.7B
Price / Cash Flow: 38.64
Annual Sales: $4.06
Price / Book: 20.91

Profitability

EPS (TTM): 3.08600
Net Income (TTM): $13.8B
Gross Margin: $28.5B
Return on Equity: 88.95%
Return on Assets: 28.14%

Novo Nordisk AS Earnings Forecast

Key Novo Nordisk AS Financial Ratios

  • The Gross Profit Margin over the past 40 years for NVO is 84.60%.
  • The Selling, General & Administrative Expenses for NVO have been equal to 26.52% of Gross Profit Margin.
  • The Research & Development expenses have been 13.97% of Revenue.
  • The Interest Expense is 0.65% of Operating Income.
  • The Net Earning history of NVO is 36.03% of Total Revenues.
  • Per Share Earnings over the last 40 years have been positive in 34 years.

Novo Nordisk AS Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: NVO
CUSIP: 670100
Website: novonordisk.com

Debt

Debt-to-Equity Ratio: 0.47
Current Ratio: 0.94
Quick Ratio: 0.74

Price-to-Earnings

Trailing P/E Ratio: 31.44
Forward P/E Ratio: 22.21

NVO Technical Analysis vs Fundamental Analysis

Sell
23
Novo Nordisk AS (NVO) is a Sell

Is Novo Nordisk AS a Buy or a Sell?

  • Novo Nordisk AS stock is rated a Sell
    The current Novo Nordisk AS [NVO] share price is $85.00. The Score for NVO is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.